T1	Participants 36 72	early stage, curable prostate cancer
T2	Participants 137 153	men aged 45-80 y
T3	Participants 194 292	prostate-specific antigen (PSA), digital rectal examination (DRE), and transrectal ultrasonography
T4	Participants 1594 1609	prostate cancer
